Abstract: The present invention provides methods of inhibiting cationic amino acid transport by means of antisense and antibody technology specific for the CAT2 transporter. Further, the present invention provides methods of treating a disease characterized by undesirable levels of nitric oxide.

Abstract: The present invention provides premalignant, serially-transplantable, hyperplastic outgrowth breast tissue lines and methods of isolating these tissue lines from mice expressing a transgene which genetically predisposes said mice to develop breast cancer. This is accomplished by implanting cells from said foci both subcutaneously and in the inguinal mammary fat pads of syngeneic, non-transgenic mice; identifying foci which grow in said fat pads but not subcutaneously as premalignant, hyperplastic outgrowths; and, establishing clonal serially-transplantable breast tissue lines from said outgrowths. Such premalignant, serially-transplantable, hyperplastic outgrowth breast tissue lines are useful for screening chemotherapeutic and chemopreventative agents as well as for identifying biomarkers of mammary preneoplasia.

Abstract: The present invention provides novel DNA sequences, recombinant DNA (rDNA) molecules, processes for producing novel T-cell proteins expressed in T-cell development, the novel T-cell proteins in substantially pure form and antibodies which bind to the novel proteins. More particularly, it relates to novel DNA sequences expressed in appropriate hosts and the novel T-cell proteins produced in these hosts. The present invention also provides novel transmembrane proteins in substantially pure form, rDNA molecules encoding transmembrane proteins and processes for producing the novel transmembrane proteins.

Abstract: The present invention provides a novel cDNA sequence (Pem), a gene product protein (Seq. id No. 1), and uses for this novel cDNA Sequence and the Pem gene product. The DNA sequence and recombinant DNA molecules of this invention are characterized in that each codes for a novel protein having the following characteristics: (1) is expressed by T lymphoma cells, (2) is not expressed in normal thymus, activated spleen cells, gut associated lymphoid tissue, or bone marrow, and is not detectable in adult brain, liver, large intestine or ovary, (3) is expressed in immortalized or cancerous cell lines, and (4) is expressed in embryonic development.

Abstract: The present invention provides novel DNA sequences, recombinant DNA (rDNA) molecules, processes for producing novel T-cell proteins expressed in T-cell development, the novel T-cell proteins in substantially pure form and antibodies which bind to the novel proteins. More particularly, it relates to novel DNA sequences expressed in appropriate hosts and the novel T-cell proteins produced in these hosts. The present invention also provides novel transmembrane proteins in substantially pure form, rDNA molecules encoding transmembrane proteins and processes for producing the novel transmembrane proteins.